Ambu cuts FY 2025/26 organic revenue growth outlook to about 10%

• Ambu cut FY 2025/26 organic revenue growth guidance to around 10% from 10-12%.
• EBIT margin before special items outlook kept at 12-14%, now expected toward the high end.
• Slower volume uptake in Anesthesia & Patient Monitoring seen driving very low-single-digit organic growth for the year.
• Endoscopy Solutions guidance maintained at +15% organic growth as the key growth driver.
• Margin outlook supported by continued operating leverage, tariff refunds.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ambu A/S published the original content used to generate this news brief on August 25, 2026, and is solely responsible for the information contained therein.